
Evonik Power to create.

Company presentation

Q2 2018 Results Roadshow





- 1. Evonik at a glance
- 2. Strategy
- 3. Financials Q2 2018
- 4. Appendix




A strong basis in Specialty Chemicals



1. Sales with top 1-3 market position by sales, production volume or capacity (depending on available data)


Three segments with differentiated management



2017 financials restated for IFRS 15




Balanced regional and end market split





1. Where not assigned to other end-customer industries | 2017 Financials


Evonik management team with clear responsibilities





"RAG-Stiftung" as long-term shareholder with focus on attractive returns

Ownership structure




RAG-Stiftung

- A foundation with the obligation to finance the perpetual liabilities arising from the cessation of hard-coal mining in Germany
- From 2019 onwards, annual cash out of ~€220 m expected
- Evonik as integral and stable portfolio element with attractive and reliable dividend policy
- RAG-Stiftung capable to cover annual cash out requirements with Evonik dividend (~€365 m dividend received in 2016)
- Long-term perspective: intention to retain a strategic shareholding of at least 25.1%



Reliable and attractive dividend policy



- Sustainable dividend growth over the last years: 7% CAGR between 2008 and 2017
- Attractive dividend yield ~ 3.7%
- Reliable dividend policy targeting:
 - dividend continuity
 - a payout ratio of ~40% of adjusted net income



1. Evonik at a glance

2. Strategy


- 3. Financials Q2 2018
- 4. Appendix



Building a best-in-class specialty chemicals company




Targeting excellence in three strategic focus areas





Target portfolio structure


Four growth engines as drivers for profitable & balanced growth





Building on our strengths

Developing our growth segments and businesses





2017 Financials

Portfolio strategy Healthy mix of growth & financing businesses

Strengthen leading positions in attractive markets

- Strong growth profile
- Above-average returns
- Focus of capital allocation (capex, R&D, acquisitions)
- Examples: High Performance Polymers, Comfort & Insulation





Strategic agenda reflected in ambitious financial targets Structurally lifting EBITDA margin and driving balanced growth





Consistently executing our strategic agenda

Levers for structural uplift in profitability and growth

	Strategic lever	Impact (p.a.)	by (year) 2020/ 2021
Synergy realization	 Realization of synergies from Air Products and J.M. Huber acquisitions 	€85 m EBITDA¹	
Cost excellence	 Targeting structural improvements in SG&A, reduction of 1,000 FTE 	€200 m EBITDA	2021 (full impact)
Innovation	 Leverage additional growth from six innovation growth fields with above-average profitability 	€1 bn additional SALES	2025
Portfolio Management	 Portfolio strategy: more balanced and more specia 	alty	





1. Total synergies of ~\$100 m; currency translation based on current EUR/USD rate of 1.18

- 1. Evonik at a glance
- 2. Strategy
- 3. Financials Q2 2018
- 4. Appendix



Our agenda for 2018 – Driving the change

Strategy execution more and more visible in accelerated financial performance



Strategy execution

- Continued execution of efficiency programs
- MMA divestment fully on track

Earnings growth

- Broad-based earnings growth across all segments
- Further progress on FCF: Q2 positive
- FY 2018 EBITDA and FCF outlook increased



Highlights Q2 2018 Broad-based earnings growth and margin expansion, positive FCF in Q2

Volume growth

+3%

Higher volumes in Nutrition & Care (+3%) and Performance Materials (+6%) Broad-based earnings growth across all three chemical segments; margin expansion mainly driven by both growth segments (NC, RE)

Adj. EBITDA and

€742 m (+16%¹)

19.2% (+1.5pp¹)

margin

Strong cash generation in Q2 in a normally negative quarter. FCF development driven by higher earnings and increased cash focus

Free cash flow

€56 m

Outlook raised


€2.6-2.65 bn

Based on strong H1, FY EBITDA and FCF outlook raised. FCF expected to be notably higher compared to 2017



1. Compared to Q2 17 | 2017 financials restated for IFRS 15


Financial highlights Q2 2018 Strong quarterly performance reflected in all KPI's



1. Portfolio effects and others | 2017 financials restated for IFRS 15

Earnings development Q2 2018


Broad-based margin expansion across all three chemical segments



1. Improvement yoy: Q2 18 vs. Q2 17 | 2017 financials restated for IFRS 15



Free Cash Flow Q2 2018 Substantial progress on FCF development: Q2 and H1 FCF clearly positive



Increase in FCF mainly driven by higher earnings and increased focus on cash-generation




Resource Efficiency

All business lines exceeding prior-year earnings



Adj. EBITDA (in € m) / margin (in %)



- Outstanding performance with all nine business lines exceeding prior-year earnings
- Continued high demand for majority of businesses, especially HPP, Silica and Coating Additives
- Stable volumes on good prior-year level. Plant utilization remains high, railway strikes in France negatively impacting volumes




Nutrition & Care Good operational performance continuing, margin further expanding



1. Mix of portfolio effects and others | 2017 financials restated for IFRS 15

Adj. EBITDA (in € m) / margin (in %)




- Good operational performance continuing, driven by focus on product mix, raw material management and strict cost optimization
- Higher volumes across virtually all business lines
- Comfort & Insulation with continued positive development, Health Care with biggest absolute earnings growth year-on-year
- Methionine with robust demand trend and yoy higher volumes; prices stable on average 2017 level (in local currencies)



Performance Materials


Strong performance in Methacrylates to continue





2017 financials restated for IFRS 15


Adj. EBITDA (in € m) / margin (in %)



- Another good quarter for Performance Materials driven by MMA/PMMA
- Volumes (+6%) driven by ongoing good demand in MMA/PMMA, supported by easier comparables (Q2 17 impacted by force majeure in Antwerp)
- C4 business with sequentially improving market conditions



Outlook 2018 EBITDA and FCF outlook raised – Strong H1, confidence for H2



FCF expected to be notably higher compared to prior year (previously: slightly higher)









2017 financials restated for IFRS 15

	Segment outlook		
Nutrition & Care	"higher earnings yoy "	previously: slightly higher	
Resource Efficiency	"perceptibly higher earnings yoy"		
Performance Materials	"higher earnings yoy "	previously: not achieve prior- year level	



Additional indications for 2018

Synergies from acquisitions
 Additional synergies of ~€25 m (Synergies 2018e: ~€40 m; 2017: ~€15 m)
 (APD Specialty Chemicals & Huber Silica)

•	Huber	Additional adj. EBITDA of ~€30 m for further eight months of consolidation (closing Sept 1 st 2017)
•	ROCE	Above cost of capital (10.0% before taxes) and around the level of last year (2017: 11.2%)
•	Capex	~€1 bn (2017: €1,078 m)
•	Free cash flow	Changed to "notably higher compared to prior year" (previously: "slightly above 2017"; 2017: €511 m)
•	EUR/USD	Changed to 1.20 EUR/USD (previously: 1.26; 2017: 1.13 EUR/USD)
•	EUR/USD sensitivity ¹	+/-1 USD cent = -/+ ~€8 m adj. EBITDA (FY basis)
•	Adj. EBITDA Services	Slightly higher than in 2017 (2017: €123 m)
•	Adj. EBITDA Corporate / Others	Slightly less negative than in 2017 (2017: -€346 m)
•	Adj. D&A	€840 m (2017: €870 m)
•	Adj. net financial result ²	~-€190 m (2017: -€175 m); increase mainly due to hybrid bond issuance in July 2017
-	Adj. tax rate	~29% (2017: 29% including positive one-time effects from US tax reform in Q4, 31% without this one-time effect)

1. Including transaction effects (after hedging) and translation effects; before secondary / market effects | 2. Guidance for "Adj. net financial result" subject to interest rate fluctuations which influence discounting effects on provisions






1. Strategy Details

- 2. Segment overview
- 3. Financials
- 4. Upcoming events



Targeting excellence in three strategic focus areas





Executing portfolio management on all levels

Achievements so far ... more to come

Major portfolio steps



Bolt-on M&A and divestments

- Acquisition of Air Products Specialty Additives
- Divestment of Methacrylates business

- Acquisition of Huber Silica
- Acquisition of Dr. Straetmans
- Sale of non-core Jayhawk agrochemicals site in Galena, Kansas (Performance Materials)



Optimization on business level

- Optimized strategic positioning for Animal Nutrition (adjust 2020)
- Business model renewal Household/ Personal Care (Oleo 2020)
- Streamlined setup of Performance Materials (Merger Functional Solutions & Agrochemicals)
- Dissolution of acrylic acid joint venture (StoHaas) in Baby Care

Portfolio management on all levels to support financial targets



		Growth trends and drivers	Product examples	Market growth
Ø	Specialty Additives "Small volume, big impact"	 More sophisticated requirements on additive effects Need for increased product performance and efficiency 	Coating Additives PU-Additives Oil Additives	5-6%
	Health & Care Preferred partner in Pharma and Cosmetics	 Increasing health-awareness and lifestyle Bio based products and environmentally-safe cosmetics 	Pharma polymers Oleochemicals Advanced biotechnology	5-6%
	Smart Materials Tailored functionalities for sustainable solutions	 Trend towards resource efficiency in high demanding applications Engineered materials and systems to fulfill high performance requirements 	Rubber Silica & Silanes High Performance Polymers Membranes	4-7%
	Animal Nutrition Comprehensive portfolio for more sustainable food chain	Sustainable nutritionImproving food quality and safety	Amino acids Probiotics	5-7%




Targeted and disciplined M&A approach

	Air Products Performance Materials	Huber Silica	Dr. Straetmans
Purchase price	~ €3.5 bn	~€600 m	~ €100 m
EBITDA margin	>20%	>20%	~20%
Market growth	~4-5%	~4-6%	~10%
Business	Highly attractive strategic fit, seamless integration into existing businesses		

Disciplined expansion in high-growth & -margin businesses with excellent strategic fit




Achieving cost excellence Targeting structural improvements in SG&A





Implementation schedule for acquisition synergies


Ramp-up on track for Air Products specialty additives and Huber silica acquisitions



1. Excluding transaction-related costs | Currency translation based on current EUR/USD rate of ~1.20


Leading in Innovation

Innovation growth fields with tangible size already today – strong growth ahead





Digital innovations provide the means for value creation Digital transformation offers broad-based opportunities





Open & performance-oriented culture

New corporate values as guidelines for cultural change

Performance

We demand excellence – and results. For our customers and our company only the best will do.

Trust

We believe in each other. Mutual respect, close collaboration and initiative are our driving forces.

Openness

We are curious and like to think outside the box. This means embracing new and diverse perspectives, sharing and open dialog.

Speed

We are ready for the future and moving fast towards it. We are agile, decisive, and quick to react.






- 1. Strategy Details
- 2. Segment overview
- 3. Financials
- 4. Upcoming events



Evonik Group Number of BL's will be reduced from 22 to 17



POWER TO CREA






Strong growth in all business lines of Nutrition & Care has been overshadowed by declining prices in Animal Nutrition and Baby Care

Animal Nutrition and Baby Care

- Earnings decline since 2015 due to normalization of methionine price and overcapacities in Baby Care (Superabsorbents)
- 2018 showing clear signs of stabilization

Other Nutrition & Care business lines


(Comfort & Insulation, Health Care, Personal Care, Household Care, Interface & Performance)



- Strong earnings growth since 2015 finally becoming visible in 2018
- Besides Comfort & Insulation (organic growth and M&A-driven), Personal Care and Health Care as major drivers




Nutrition & Care Business Line overview (1/2)





1. Company estimates for relevant markets based on multiple research reports

Nutrition & Care Business Line overview (2/2)





1. Company estimates for relevant markets based on multiple research reports

Spotlight on Nutrition & Care

Pioneer solutions for nutrition, healthcare, personal care and everyday living

A high-value portfolio shaped by the individual needs of our customers





Portfolio Management – Animal Nutrition

Advance leadership position by growth initiatives and efficiency gains

Strategic review process conducted in Animal Nutrition


Broaden portfolio

...beyond amino acids:

- Probiotics
- CreAMINO[®]
- Omega-3 fatty acids
- Diagnostics



Manage production setup



- Closure of uneconomic sites (e.g. Threonine in Hungary)
- Synergy realization for lysine and omega-3 production in Blair, NE





- Process innovations to improve Methionine production cost base
- Streamlining supply chain
- Evolution of sales & marketing: strict cost-to-serve approach


Double-digit annual growth rates

€50 m p.a. efficiency improvements ("adjust 2020")

- → First savings already in 2018; full savings by 2020
- → Reduction of ~270 FTE across all functions




Building a "Care Solutions" Powerhouse Combining Personal Care & Household Care business lines




Evonik Care Solutions

Leading partner for Care applications: Translating technologies into marketable solutions



POWER TO CREATI

Business Line Care Solutions: RHEANCE® Glycolipids / Biosurfactants Biotechnology for a sustainable step change in cosmetic ingredients



Consumer products: Multifunctional solution for gentle cleansing enabling 100% biodegradable skin and hair care products with a strong performance and eco-profile


Unique process – Unique products

- Nature-identical biomolecules
- By fermentation of sugars only
- No tropical oils needed
- Based on strong Evonik biotech platform



Evonik Health Care

An enabling portfolio of products, technologies & services for high-value partnerships



POWER TO CREAT

Meet the Management 2018 - Nutrition & Care

Business Line Health Care: AvailOm®

The highest-load Omega-3 powder for cardiovascular and cognitive health

- High-concentration lysine powder complex
 - Minimum of 45 percent EPA and DHA by weight
 - 3-5 times more bioavailable than standard Omega-3 softgels
- Directly compressible to easily combine with other ingredients
- Unmatched protection against oxidation: stable for at least 3 yrs.
- Clearance for use in the U.S., Europe and other markets
- New formulation opportunities for new consumer products


A small, single tablet has the same uptake of EPA and DHA as two fish oil capsules






DHA to help maintain normal brain function with EPA + DHA to maintain normal heart function








Resource Efficiency Innovative products for resource-efficient solutions






Resource Efficiency Business Line overview (1/3)



POWER TO CREA

1. Company estimates for relevant markets based on multiple research reports


Resource Efficiency Business Line overview (2/3)




POWER TO CREA

1. Company estimates for relevant markets based on multiple research reports

Resource Efficiency Business Line overview (3/3)










Resource Efficiency

Diversified auto product portfolio with broad OEM and replacement exposure



RE sales split 2017

58



Silica market

- Market growth: 4-6%, expected to stay clearly above GDP
- Main growth driver: eco-friendly and custom-tailored, steadily new applications
- Market access: reliable and cost competitive raw material base crucial

Evonik positioning

- Only supplier for both, fumed and precipitated silica as well as metal oxides
- Superior process technology (e.g. integrated silica-silane production platform)
- In-house "Verbund" and external raw material partners
- Global production platform (26 sites)
- Regional customer proximity (~200 M&S employees, presence in 100 countries)
- Unique product portfolio with >100 larger volume specialties as well as customized solutions







Business Line Silica

Innovation pipeline goes beyond the existing business

Re-innovate product solutions for **existing markets**

New ULTRASIL® grade for SUV tires

- Growing demand for larger SUVs tires
- Challenge for tire manufacturers: Sufficient stiffness in spite of their size
- ULTRASIL[®] 7800 GR offers the right mix to give SUV tires the needed stiffness, low rolling resistance and improved "grip"
- This reduces CO2-emissions and lowers fuel consumption by up to 8%



60



Tap into **new markets** via application development

AEROXIDE® as additive in Li-ion batteries


- Li-ion battery market shows a continued high growth rate, ultimately fueled by the electric vehicle market
- Key industry challenges are performance, life-time, and safety of the battery
- AEROXIDE[®] fumed metal oxides from Evonik help addressing these challenges as additives in Li-ion battery components



Create **new technology options to** enlarge the playing <u>field</u>

SPHERILEX® a new silica class

- New product class, unique, patented manufacturing process and materials
- Able to produce novel, precipitated silica morphologies with traditional raw materials
- Ability to control pore size, pore size distribution and surface area
- Applications examples: oral care, cosmetics and coatings







Start-up	Investment	Rationale	Precipitated Silica	Fumed Silica
2017	Acquisition of Huber Silica Business	Excellent complementary fit for high-growth and resilient Silica business	×	
2018	New precipitated silica plant in South Carolina, USA	World-scale facility close to production plants of large tire manufacturers	×	
2019	Capacity expansion, Antwerp 2020	Investment in additional fumed silica capacities in Antwerp		×
2020	Capacity expansion in Adapazari, Turkey	Investment into additional precipitated silica capacities mainly for tire applications	×	
2021	Joint Venture with Wynca to produce fumed silica	First fumed silica plant in the attractive Chinese market with strong local partner		×



Business Line High Performance Polymers

Evonik to expand its leading position in powdered PA 12 for Additive Manufacturing

- Evonik VESTOSINT products have clear USP for powder-based 3D printing (e.g. chemicals resistance, melting point etc.)
- Strong growth potential with ongoing transition from prototyping to manufacturing
- Strong relationships with leading printer manufacturers (e.g. EOS, HP)
- New polyamide 12 powder plant in Marl
 - Investment in the mid double-digit million € range
 - New facility primarily produces high-performance powders for the 3D printing market, which is expanding heavily with double-digit growth rates





Business Line High Performance Polymers

Several growth markets benefitting from unique Polyamide 12 properties



Mid-term CAGR¹

VESTOSINT[®] >15% p.a.

PA12 powders for various powder based 3D technologies

Unique PA12 benefit: powder quality (shape & precision)

Automotive



VESTAMID®

5-10% p.a.

E.g. fuel lines for conventional vehicles & cooling lines for battery packages

Unique PA12 benefit: impact & chemical resistance

Oil and Gas



VESTAMID[®] NRG >10% p.a.

- PA12 for large diameter pipes for offshore Oil and Gas production
- PA12 for onshore gas distribution

Unique PA12 benefit: high strength & chemical resistance

Medical



VESTAMID[®] Care 5-10% p.a.

- Heart catheters and tubes
- Durable medical equipment in imaging devices
 Unique PA12 benefit:
 biocompatibility



1. Evonik estimates

Business Line Coating Additives

Serving the high demand for eco-friendly, water-borne coatings

Challenges & needs:


- Chinese government introduced new coating-regulations to prevent solvent-borne coatings
- First step: only water-borne coatings allowed for container-paintings (China accounts for 90% of worldwide containers-production)
- Increasing use of waterborne coatings also for e.g., wood coatings, protective coatings, industrial coatings

Approach & Solution:

- Evonik as leading player for water-borne coatings
- Strong and innovative portfolio to serve the growing demand for water-borne coatings and applications from various industries
- → Additional double digit million € sales in 2018




Water-borne coatings market






Performance Materials

Integrated production platforms for efficient production of rubber and plastic intermediates



Performance Materials Business Line overview (1/2)





1. Company estimates for relevant markets based on multiple research reports

Performance Materials Business Line overview (2/2)


	Agrochemicals & Polymer Additives	Functional Solutions	CyPlus Technologies
Key products	 Triacetonamine Crosslinkers Precursors for crop protection 	 Alkoxides (e.g. sodium methylate) 	Sodium cyanidePotassium cyanide
Main Applications	 Polymer additives Agro chemicals Optical brighteners Photovoltaic 	 Catalysts for biodiesel production 	Precious metals miningFine chemicals
Market position ¹	• n.a.	 # 1 in alkoxides 	■ n.a.
Main competitors	 Lanxess Weylchem 	BASFSmotec	AGRDuPontOrica



1. Company estimates for relevant markets based on multiple research reports

Streamlined setup of Performance Materials segment

Merger Functional Solutions & Agrochemicals business lines



Merger Functional Solutions & Agrochemicals: Bundling of competencies

- Complexity reduction:
 - On segment level: Going forward, only 2 business lines in Performance Materials
 - On business line level: Reduction of product lines
 from 5 to 3 (in new Functional Solutions business line)


Efficiency improvement:

- Further optimization of Chlorine Verbund
- More efficient supply chain organization
- Bundling of mgmt. positions and support functions



Performance Intermediates (C4 chain)

Fully integrated production platform in Europe





Strategic project to further strengthen our C4 chain



Target

C4 "Verbund" optimization through:

- Increased productivity
- Optimization of supply
- Higher product flexibility

Addressed levers

- Better utilization and debottlenecking of existing plants
- Better catalysts
- Improved product mix



Approach

Holistic evaluation of "Verbund" structure

- Interdisciplinary teams
- Agile cooperation methods like Scrum
- Scope: Products & Markets, Processes & Plants, Innovation

Financial impact

Consequent focus on efficiency

- Realization of main strategic targets while spending significantly less capex
- Capex savings of ~55% after completion



Portfolio Management – Methacrylates

Divestment of Methacrylates business




- Methacrylates in good shape and well positioned
- C2 technology "LiMA" opens new opportunities for the business
- Business perspectives cannot be realized with current portfolio role
- Driving process to find a new owner

Divestment process for Methacrylates initiated



The new Verbund pools methacrylate competencies

Our claim: the world's leading methacrylate business




* Product groups: Protective Coatings & Inks , Roadmarking & Flooring



Proprietary C2 MMA technology with disruptive potential

LiMA – C2 MMA production technology



Pilot plant with >10,000 hrs

Intelligent process ...

proprietary catalyst with high yield and selectivity

Efficient new catalyst ...

accesses shale gas as raw-material source

Best-in-class ...

in environmental impact (emission, energy)

Methyl Methacrylate (MMA) Production by Evonik LiMA[®] Process



Process Economics Program

"Based on our analysis, we believe that LiMA has a strong potential to produce MMA at lower costs and with lesser environmental impact than Lucite's Alpha process."

Advantages of LiMA

IHS PEP Review

11111-21-1-1-21-1-11-11-21-21-1-2-24444




- 1. Strategy Details
- 2. Segment overview
- 3. Financials
- 4. Upcoming events




Recent cost initiatives

Program to achieve cost excellence in admin and selling initiated



Capex 2018 ~€1 bn despite additional €150 m for Me6 plant



- Additional ~€150 m capex for Me6 plant in Singapore compared to prior year (total Me6 spending in 2018: ~€300 m)
- Overall lower capex in 2018 due to high capex discipline in form of reduced maintenance capex or postponement of projects


Top growth projects 2018

- Methionine 6 (Me6)
 - More than half a billion €, 2016-2019
 Singapore
- Extension precipitated silica
 ~€100 m; 2016-2018
 - Charleston, South Carolina
- Extension of fumed silica
 - Upper double-digit million €, 2017-2019
 Antwerp
- Veramaris (Green Ocean)
 - ~€100 m (Evonik share), 2017-2019
 Blair, Nebraska




Investments

Capex with significant decrease since 2013 – focus on growth segments



- Capex focus on the two growth segments
- Sustainable capex level going forward: ~€900 950 m
- Sizable investment projects will result in slightly elevated levels during project time (e.g. second Methionine plant in Singapore with more than half a billion € of Capex between 2016 and 2019, peaking in 2018)





Investment projects successfully completed ...

Polyimide membrane exp.

Austria

Rationale: strengthen growth in attractive gas separation market and position as technology leader for membrane-based gas separation

PA12 powder exp.

Germany

Rationale: additional capacities target highly attractive growth markets (e.g. 3-D printing) and solidifies leading market position for PA 12

Specialty silicones plant China

Rationale: local production increases flexibility in the fast growing market for specialty silicones (e.g. used in polyurethane, paints, and coatings)

aints, and coatings)



... and projects with start-up planned for 2019

Veramaris JV (Green Ocean)

United States Start-up: 2019 Volume: ~€100 m



Extension of fumed silica Belgium

Start-up: 2019 Volume: upper double-digit million €

New methionine plant (Me6) Singapore


Start-up: 2019 Volume: >€500 m







Financial policy Maintaining a solid investment grade rating



Both rating agencies affirmed its ratings in 2017 based on


- Strong business profile underpinned by significant size and leading global market positions
- Greater-than-peer diversity in terms of end-markets and product range
- Acquisitions of Air Products Specialty Additives and Huber Silica enhances the specialty chemicals portfolio
- Supportive financial policy and management's commitment to a solid investment-grade rating

Maintaining a solid investment grade rating is a central element in our financing strategy



Debt structure Well balanced maturity profile

(in € m as of June 30, 2018)




- Well balanced debt maturity profile with no single maturity greater than €750 m
- Long-term capital market financing secured under favorable conditions: average coupon of only 0.74% p.a. on €3.15 bn senior bonds and 2.125% p.a. on €0.5 bn hybrid bond
- Undrawn €1,750 m syndicated revolving credit facility maturing June 2023 (plus oneyear extension option)² provides comfortable level of back-up liquidity

1. Formal lifetime of 60 years; first redemption right for Evonik in 2022 2. Initial tenor until June 2022; first extension option until June 2023 exercised as per April 2018



Development of net debt and leverage over time

(in € m)



- Increase of net financial debt during Q2 due to dividend payment for fiscal year 2017 (€536 m)
- Change in discount rate for Germany (from 2.00% to 1.75 %, as per March 31, 2018) resulting in an increase in pension provisions
- Net financial debt development 2017 mainly driven by acquisition-related purchase price payments (in particular APD and Huber Silica)
- Pension provisions are partly balanced by corresponding deferred tax assets of ~€1.2 bn
- More than half of total net debt consists of long-dated pension obligations; average life of DBO exceeds 15 years


Evonik Group global discount rate (in %)²

Evonik discount rate for Germany (in %)



1. Total leverage defined as (net financial debt - 50% hybrid bond + pension provisions) / adj. EBITDA LTM | 2. Calculated annually

Pensions Pension funding overview as of 31 December 2017




- Pensions very long-term, patient debt (>16 years) with no funding obligations in Germany
- DBO level of €11.6 bn yoy stable (interest rate unchanged at 2.00%)
- Funding ratio increased to ~70% mainly due to positive development of pension asset

Funding level increased to ~70%



Pensions Sensitivity to discount rate changes





1. Excluding any effects from potential actuarial changes and changes in the valuation of plan assets


Pensions Breakdown of P&L and cash flow effects

P&L	in € m	P&L item / KPI	2016	2017	Annual report '17
	Current service costs	Adj. EBITDA	-180	-200	p. 131
	Interest costs	Net interest expense	-297	-243	p. 131
	Exp. return on plan assets	Net interest expense	+207	+166	p. 132
	Other	Adj. EBITDA	-44	-33	р. 133
	Total pension expense		-316	-310	

Cash flow	in € m 2016		2017	Annual report '17	
	Benefits paid	From	-428	-462	p. 131
	Benefits paid from plan assets	defined benefit	+181	+210	p. 132
	Contribution to plan assets (excl. CTA)	plans	-152	-186	p. 132
	Payments under defined contribution plans	-166	-178	p. 133	
	Total cash out for pensions (excl. CTA)		-565	-616	




Transition of "Changes in provisions for pensions" in Operating Cash Flow





Based on 2017 financials

Financial track record





Segment overview by quarter

Sales (in € m)	FY 2016	Q1/17	Q2/17	Q3/17	Q4/17	FY 2017	Q1/18	Q2/18
Nutrition & Care	4,316	1,120	1,163	1,110	1,114	4,507	1,119	1,189
Resource Efficiency	4,473	1,360	1,367	1,358	1,308	5,393	1,398	1,479
Performance Materials	3,245	959	910	913	970	3,751	995	1,025
Services	683	193	174	172	178	717	163	172
Corporate / Others	15	4	4	3	3	15	3	3
Evonik Group	12,732	3,636	3,618	3,556	3,573	14,383	3,678	3,870
Adj. EBITDA (in € m)	FY 2016	Q1/17	Q2/17	Q3/17	Q4/17	FY 2017	Q1/18	Q2/18
Nutrition & Care	1,006	187	201	188	172	747	209	222
Resource Efficiency	977	297	318	311	247	1,173	325	366
Performance Materials	371	157	168	172	161	658	179	196
Services	151	43	38	49	3	133	49	35
Corporate / Others	-340	-89	-85	-80	-100	-354	-83	-77
Evonik Group	2,165	595	640	640	483	2,357	679	742

2017 financials restated for IFRS 15







Breakdown of raw material spend¹ (examples)

Silicon metal



1. Raw material spend 60% of total procurement volume in 2017

Management compensation

Fixed salary ~1/3	 To be paid in cash for each financial year on a monthly basis 				
Bonus ~1/3	 Pay-out calculated on the basis of the achievement of focused KPIs; aligned to mid-term strategic targets: 1. Progression towards EBITDA margin target 2. EBITDA growth (yoy) 3. Contribution to group's FCF target 4. Accident performance 	 Factor of between 0.8 and 1.2 to take into account the achievement of further individual targets Bonus capped at 200% of initial target 			
Long-term incentive plan ~1/3	 Granted LTI target amount is calculated in virtual shares (4-year lock-up) Value of LTI to mirror the development of Evonik's share price (incl. dividends) Amount payable is determined by two performance elements 	 Absolute performance: Real price of the Evonik share Relative performance against external index benchmark (MSCI Chemicals) Bonus capped at 300% of initial amount To be paid out in cash after lock-up period 			




Six strong Innovation Growth Fields within the growth engines

Leveraging our core competencies into new highly attractive markets





Our sustainability targets 2017 and beyond





Sustainability Ratings & Rankings: Evonik well positioned

Our commitment has been recognized by

- ✓ CDP Climate Change (A-, Index-Leader MDAX)
- ✓ CDP Water (B)
- ✓ Oekom Research (prime standard B-)
- ✓ Sustainalytics (among Top 5 within chemical sector)
- ✓ Together for Sustainability/ecoVadis ("Gold Standard")
- ✓ FTSE4Good Europe, FTSE4Good Global
- ✓ STOXX[®] Global ESG Leaders





Appendix

- 1. Strategy
- 2. Segment overview
- 3. Financials
- 4. Upcoming events



Conferences & Roadshows				
26 September	Bernstein SDC Conference, London			
26 September	Berenberg/Goldman Sachs German Corporate Conference, Munich			
27 September	Baader Investment Conference, Munich			
27 September	J.P. Morgan Investor Forum, Milan			

Upcoming Events & Reporting Dates				
6 November 2018	Q3 2018 reporting			
5 March 2019	FY 2018 reporting			



Evonik Investor Relations team



Tim Lange Head of Investor Relations

+49 201 177 3150 tim.lange@evonik.com



Eva Frerker Investor Relations Manager

+49 201 177 3142 eva.frerker@evonik.com



Joachim Kunz Investor Relations Manager

> +49 201 177 3148 joachim.kunz@evonik.com



Daniel Györy Investor Relations Manager

+49 201 177 3147 Daniel.gyoery@evonik.com



Fabian Schwane Investor Relations Manager

+49 201 177 3149 fabian.schwane@evonik.com



janine.kanotowsky@evonik.com

Janine Kanotowsky

Team Assistant

+49 201 177 3146

Kai Kirchhoff Investor Relations Manager

+49 201 177 3145 kai.kirchhoff@evonik.com



In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.



